Preterm Birth and PROM Testing Market, By Product Type (Kits and Reagents, Instruments, and Consumables), By Test Type (Pelvic Exam, Ultrasound, Uterine Monitoring, Biomarker Testing, and Others), By End User (Hospitals, Diagnostics Laboratories, Outpatient Clinics, Research Centers, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East)

Published In : Dec 2023

Code : CMI6403

Pages :170

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments

New product launches

In April 2023, Mediclinic Southern Africa, a private hospital company, announced the launch of safe, non-invasive prenatal testing (NIPT) for pregnant parents as part of its DNA-based diagnostic and clinical interpretation services. This is a new product that was added once Mediclinic Ancestry testing was introduced in 2023.
In October 2022, Ambry Genetics, a clinical diagnostic testing company and a division of REALM IDx, a biotechnology company, launched a new reproductive health initiative powered by its Comprehensive Assessment Risk and Education (CARE) Program, a digital platform designed to increase access to non-invasive prenatal testing (NIPT), also known as carrier screening, and support patients in making decisions.
In July 2022, GE Healthcare, a medical technology company, launched its most advanced ultrasound, the next-generation Voluson Expert 22. This latest addition to GE Healthcare’s award-winning Women’s Health portfolio utilizes graphic-based beam former technology, which produces higher quality images and offers greater flexibility in imaging functions during pregnancy.

Acquisitions and partnerships

In February 2022, Sera Prognostics Inc., a pregnancy company focused on improving maternal and neonatal health by providing innovative pregnancy biomarker, announced the execution of a partnership with MultiPlan, a healthcare management company. The agreement will help expand access to the PreTRM Test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth.
In January 2022, QIAGEN N.V., a clinical diagnostic company, announced a partnership with Atila BioSystems, a biotechnology company, to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN N.V’s dPCR franchise. NIPT requires only a blood sample from the mother, and replaces more invasive testing methods such as amniocentesis that can endanger the fetus and mother.
In June 2019, Invitae Corporation, a medical genetics company, announced that it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately-held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS)